MALVERN, PA — In a significant development for Alzheimer’s Disease (AD) research, Annovis Bio, Inc. (NYSE: ANVS) has unveiled new data from a study indicating that buntanetap, an innovative oral molecule, may play a crucial role in inhibiting the production of amyloid precursor protein (APP), a key factor in the progression of AD. This recent publication sheds light on the potential of buntanetap to alter the trajectory of early-stage Alzheimer’s by targeting the neurotoxic proteins responsible for the disease’s hallmark symptoms.
Buntanetap operates by selectively binding to an iron-responsive element in the mRNA of APP and other neurotoxic proteins, effectively inhibiting their translation. The study, completed in 2021, utilized Stable Isotope Labeling Kinetics (SILK) to assess the pharmacodynamic effects of buntanetap on APP mRNA translation. SILK is a cutting-edge technique that measures the synthesis, steady state, and degradation of proteins in the cerebrospinal fluid (CSF), allowing for the detection of subtle protein changes that traditional CSF sampling methods cannot identify.
The randomized, double-blind, placebo-controlled study involved participants receiving varying doses of oral buntanetap (ranging from 60 mg to 180 mg per day) or a placebo over a 25-day period. Following this, patients underwent a catheterization process in the lumbar spine for 36 hours to measure the total synthesis, processing into amyloid beta (Aβ), and degradation of APP. The study’s findings are particularly noteworthy, as they demonstrate no dose-dependent adverse effects of buntanetap compared to the placebo, highlighting the drug’s safety and tolerability.
Moreover, the application of multiparameter modeling to APP kinetics revealed a dose-dependent reduction in APP production attributable to buntanetap. While the results did not achieve statistical significance across all parameters due to the small sample size, the observed trend aligns with buntanetap’s mechanism of action as a translational inhibitor of APP. This suggests a promising avenue for further research into buntanetap’s efficacy in lowering the production of amyloid beta, a substance closely linked to the development and progression of Alzheimer’s Disease.
The implications of these findings are profound for the field of neurology and for millions worldwide affected by Alzheimer’s Disease. As the global population ages, the quest for effective treatments for AD becomes increasingly urgent. Buntanetap’s potential to inhibit the production of neurotoxic proteins at the early stages of Alzheimer’s opens new doors for therapeutic interventions, potentially offering hope to patients and families grappling with the disease.
Annovis Bio’s continued exploration of buntanetap highlights the importance of innovative approaches in tackling complex neurological disorders. As further studies are conducted to validate these initial findings, the medical community remains cautiously optimistic about buntanetap’s role in shaping future treatment paradigms for Alzheimer’s Disease.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.